Metastatic breast cancer trials in Spain

In Spain 73 Also abroad 609

73 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Not yet taking people in Spain
A Phase I First-in-Human Dose Escalation Trial to Evaluate the Safety and Efficacy of ARI-HER2 (HER2BBz CAR-T Cells) in Patients with HER2Positive Advanced Breast Cancer
Where
Barcelona, Madrid, Pamplona
Age
18 years to 64 years
People
18
Run by
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
See details and how to join2026-527365-30-00
Phase 2Not yet taking people in Spain
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
Where
L'Hospitalet de Llobregat, Madrid
Age
18 years and over
People
90 worldwide
Run by
Delcath Systems Inc.
See details and how to joinNCT06875128 · EU 2025-521966-91-00
Phase 3Taking people
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Where
A Coruña, Barcelona, Bilbao, Granada, Jaén, Madrid, Málaga, Zaragoza
Age
18 years and over
People
400 worldwide
Run by
Pfizer
See details and how to joinNCT07062965 · EU 2025-520566-22-00
Phase 3Not yet taking people in Spain
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Where
Badajoz, Badalona, Barcelona, Burgos, Donostia / San Sebastian, Huelva, Jaén, Las Palmas de Gran Canaria, Majadahonda, Málaga, Murcia, Oviedo, Palma de Mallorca, Pontevedra, Pozuelo de Alarcón, Santander, Toledo, Zaragoza
Age
18 years to 130 years
People
150 worldwide
Run by
AstraZeneca
See details and how to joinNCT07647328
Phase 3Taking people
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Where
Barcelona, Córdoba, Madrid, Pozuelo de Alarcón, Seville, Valencia
Age
18 years and over
People
1,200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06312176 · EU 2023-504918-29-00
Phase 1/2Taking people
To compare the Safety and activity of GDC-4198 Alone and in Combination with Giredestrant against Abemaciclib and Giredestrant in Participants with Breast Cancer
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Valencia
Age
18 years and over
People
73 worldwide
Run by
Genentech Inc.
See details and how to join2025-521128-31-00
Phase 3Not yet taking people in Spain
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Where
A Coruña, Badajoz, Barcelona, Cáceres, L'Hospitalet de Llobregat, Lleida, Madrid, Murcia, Santiago de Compostela, Valencia
Age
18 years and over
People
1,180 worldwide
Run by
Celcuity Inc
See details and how to joinNCT06757634 · EU 2024-518933-28-01
No phaseTaking people
A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)
Where
A Coruña, Albacete, Alcorcón, Alicante, Ávila, Barcelona, Bilbao, Córdoba, Elche, Fuenlabrada, Las Palmas de Gran Canaria, Leganés, León, Lugo, Madrid, Málaga, Manresa, Murcia, Palma de Mallorca, Pamplona, Sagunto, Salamanca, San Sebastián, San Sebastián de los Reyes, Santa Cruz de Tenerife, Seville, Terrassa, Toledo, Valencia, Zaragoza
Age
18 years and over
People
1,867
Run by
Spanish Breast Cancer Research Group
See details and how to joinNCT02819882
Phase 2Taking people
Phase II, Prospective, Randomized, Proof-of-concept Study to Evaluate the Effects of a Personalized Dietary Intervention in Women With Advanced Gynecologic or Breast Tumors Treated With Antibody-Drug Conjugates (ADCs).
Where
Madrid
Age
18 years and over
People
100
Run by
TNC Nutrición Terapéutica S.L.
See details and how to joinNCT07406789
Phase 2Taking people
A TWO-STAGE, SINGLE-ARM, PHASE II STUDY OF ZONGERTINIB PLUS FULVESTRANT IN PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE/HER2- NEGATIVE ADVANCED BREAST CANCER HARBORING HER2 MUTATIONS (AGATHA)
Where
Barcelona, Bilbao, Córdoba, Elche, Girona, L'Hospitalet de Llobregat, Lleida, Madrid, Málaga, Palma, Reus, Santander, Sant Cugat del Vallès, Santiago De Compostela, Sevilla, Valencia
Age
18 years and over
People
25 worldwide
Run by
Medica Scientia Innovation Research S.L.
See details and how to join2026-525328-10-00
Phase 1/2Taking people
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Where
A Coruña, Barcelona, Málaga, Pozuelo de Alarcón, Sant Cugat del Vallès, Sevilla
Age
18 years to 130 years
People
695 worldwide
Run by
AstraZeneca
See details and how to joinNCT05417594 · EU 2023-504984-17-00
Phase 1Taking people
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Where
Barcelona, Madrid
Age
18 years and over
People
180 worldwide
Run by
Olema Pharmaceuticals, Inc.
See details and how to joinNCT06784193
Phase 3Taking people
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
Where
Barcelona, Coruña, Granada, Madrid, Sevilla, Valencia
Age
18 years and over
People
100 worldwide
Run by
AstraZeneca
See details and how to joinNCT07205822 · EU 2025-521904-23-00
Phase 2Taking people
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Where
Alicante, Barakaldo, Barcelona, Bilbao, Cáceres, Granada, Huelva, Jaén, Lleida, Madrid, Sevilla, Valencia
Age
18 years and over
People
225 worldwide
Run by
Puma Biotechnology, Inc.
See details and how to joinNCT06369285 · EU 2024-511497-79-00
Phase 1Taking people
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Where
Barcelona, Lleida, Madrid, Pozuelo de Alarcón, Valencia
Age
18 years and over
People
392 worldwide
Run by
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
See details and how to joinNCT06625775 · EU 2024-519445-29-00
Phase 1/2Not yet taking people in Spain
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
Where
Badalona, Barcelona, Granada, Madrid, Málaga, Pamplona, Pozuelo de Alarcón, Santa Cruz de Tenerife, Santiago de Compostela, Seville
Age
18 years and over
People
220 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT07701941 · EU 2024-517541-14-00
Phase 3Taking people
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Where
Alicante, Barcelona, Granada, León, Lleida, Madrid, Murcia, Sevilla, Valencia, Zaragoza
Age
18 years and over
People
1,000 worldwide
Run by
Olema Pharmaceuticals, Inc.
See details and how to joinNCT07085767 · EU 2025-522873-12-00
Phase 2Not yet taking people in Spain
Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.
Where
Barcelona, Madrid
People
51 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07679269 · EU 2026-525890-38-00
Phase 1Not yet taking people in Spain
A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
Where
Barcelona, L'Hospitalet de Llobregat
Age
18 years and over
People
62 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-521702-18-00
No phaseTaking people
EORTC Metastatic Breast Cancer Module Development
Where
Pamplona
Age
18 years and over
People
568 worldwide
Run by
University of Leeds
See details and how to joinNCT07806266
Phase 2Taking people
LuMIERE: A Phase 1/2, Multicenter, Open label, Non randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu-FAP-2286 in Participants with an Advanced Solid Tumor
Where
A Coruña, Badalona, Madrid
Age
18 years and over
People
36 worldwide
Run by
Novartis Pharma AG
See details and how to joinNCT04939610 · EU 2023-508995-12-01
Phase 1/2Taking people
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Where
Barcelona, Madrid
Age
18 years to 100 years
People
280 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06726148 · EU 2024-517281-42-00
Phase 3Taking people
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
Where
A Coruna, Alicante, Alzira, Badalona, Barcelona, Bilbao, Burgos, Cáceres, Castello De La Plana, Granada, Jaén, Las Palmas de Gran Canaria, León, Lleida, Madrid, Majadahonda, Murcia, Palma, Pamplona, Reus, San Cristóbal de La Laguna, Santander, Santiago de Compostela, Sant Joan d'Alacant, Sevilla, Valencia, Zaragoza
Age
18 years and over
People
300 worldwide
Run by
MedSIR
See details and how to joinNCT06382948 · EU 2024-512926-27-00
No phaseNot yet taking people in Spain
DESTINY Breast Respond HER2-(Ultra)Low Europe
Where
Albacete, Alicante, Alzira, Barakaldo, Barcelona, Bilbao, Cáceres, Cadiz, Córdoba, Elche, Galdakao, Granada, Jaén, León, Logroño, Lugo, Madrid, Murcia, Oviedo, Palencia, Palma, Palma de Mallorca, Pontevedra, Reus, Sabadell, Salamanca, San Cristóbal de La Laguna, Santander, Sant Cugat del Vallès, Valencia, Valladolid, Vigo Pontevedra, Zaragoza
Age
18 years and over
People
2,295 worldwide
Run by
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
See details and how to joinNCT05945732
No phaseTaking people
AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.
Where
A Coruña, Barcelona, Cáceres, Castellon, Lleida, Madrid, Seville, Valencia
Age
18 years and over
People
1,000 worldwide
Run by
Jules Bordet Institute
See details and how to joinNCT02102165